These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24384881)

  • 1. Participant survey results from the Starting Hizentra Administration with Resources and Education (SHARE) program.
    Duff C; Riley P; Zampelli A; Murphy E
    J Infus Nurs; 2014; 37(1):21-8. PubMed ID: 24384881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
    Stein MR; Koterba A; Rodden L; Berger M
    Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.
    Shapiro R
    Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.
    Mallick R; Jolles S; Kanegane H; Agbor-Tarh D; Rojavin M
    J Clin Immunol; 2018 Nov; 38(8):886-897. PubMed ID: 30465179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why I use subcutaneous immunoglobulin (SCIG).
    Shapiro RS
    J Clin Immunol; 2013 Jan; 33 Suppl 2():S95-8. PubMed ID: 23264027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
    Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
    J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.
    Wasserman RL
    Immunotherapy; 2017 Sep; 9(12):1035-1050. PubMed ID: 28871852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies.
    Patel NC; Torgerson T; Thakar MS; Younger MEM; Sriaroon P; Pozos TC; Buckley RH; Morris D; Vilkama D; Heimall J
    J Clin Immunol; 2023 Oct; 43(7):1557-1565. PubMed ID: 37266769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
    Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
    Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency.
    Gupta S; Kobayashi RH; Litzman J; Cherwin L; Hoeller S; Kreuwel H
    Expert Rev Clin Immunol; 2023 Jan; 19(1):7-17. PubMed ID: 36346032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
    Shapiro RS
    Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
    Berger M; Rojavin M; Kiessling P; Zenker O
    Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
    Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
    J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis.
    Shabaninejad H; Asgharzadeh A; Rezaei N; Rezapoor A
    Expert Rev Clin Immunol; 2016; 12(5):595-602. PubMed ID: 26902306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
    Kobayashi RH; Litzman J; Rizvi S; Kreuwel H; Hoeller S; Gupta S
    Immunotherapy; 2022 Mar; 14(4):259-270. PubMed ID: 34986666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.